The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors
- PMID: 15125842
- DOI: 10.1016/s1097-2765(04)00211-4
The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors
Abstract
Skeletal muscle size depends upon a dynamic balance between anabolic (or hypertrophic) and catabolic (or atrophic) processes. Previously, no link between the molecular mediators of atrophy and hypertrophy had been reported. We demonstrate a hierarchy between the signals which mediate hypertrophy and those which mediate atrophy: the IGF-1/PI3K/Akt pathway, which has been shown to induce hypertrophy, prevents induction of requisite atrophy mediators, namely the muscle-specific ubiquitin ligases MAFbx and MuRF1. Moreover, the mechanism for this inhibition involves Akt-mediated inhibition of the FoxO family of transcription factors; a mutant form of FOXO1, which prevents Akt phosphorylation, thereby prevents Akt-mediated inhibition of MuRF1 and MAFbx upregulation. Our study thus defines a previously uncharacterized function for Akt, which has important therapeutic relevance: Akt is not only capable of activating prosynthetic pathways, as previously demonstrated, but is simultaneously and dominantly able to suppress catabolic pathways, allowing it to prevent glucocorticoid and denervation-induced muscle atrophy.
Similar articles
-
Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes.Metabolism. 2013 Oct;62(10):1495-502. doi: 10.1016/j.metabol.2013.05.018. Epub 2013 Jul 15. Metabolism. 2013. PMID: 23866982
-
AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes.J Cell Biochem. 2009 Oct 1;108(2):458-68. doi: 10.1002/jcb.22272. J Cell Biochem. 2009. PMID: 19639604
-
Resveratrol prevents TNF-α-induced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes.Int Immunopharmacol. 2014 Apr;19(2):206-13. doi: 10.1016/j.intimp.2014.02.002. Epub 2014 Feb 15. Int Immunopharmacol. 2014. PMID: 24534773
-
Signalling pathways that mediate skeletal muscle hypertrophy and atrophy.Nat Cell Biol. 2003 Feb;5(2):87-90. doi: 10.1038/ncb0203-87. Nat Cell Biol. 2003. PMID: 12563267 Review.
-
Skeletal muscle hypertrophy and atrophy signaling pathways.Int J Biochem Cell Biol. 2005 Oct;37(10):1974-84. doi: 10.1016/j.biocel.2005.04.018. Int J Biochem Cell Biol. 2005. PMID: 16087388 Review.
Cited by
-
Muscle atrophy induced by overexpression of ALAS2 is related to muscle mitochondrial dysfunction.Skelet Muscle. 2021 Mar 30;11(1):9. doi: 10.1186/s13395-021-00263-8. Skelet Muscle. 2021. PMID: 33785075 Free PMC article.
-
David J. Glass elected to the U.S. National Academy of Sciences.Skelet Muscle. 2024 Jul 9;14(1):14. doi: 10.1186/s13395-024-00343-5. Skelet Muscle. 2024. PMID: 38982533 Free PMC article. No abstract available.
-
Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure.Heart Fail Rev. 2013 Sep;18(5):557-66. doi: 10.1007/s10741-012-9349-4. Heart Fail Rev. 2013. PMID: 23090715 Review.
-
Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure.J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):261-74. doi: 10.1002/jcsm.12086. Epub 2015 Oct 27. J Cachexia Sarcopenia Muscle. 2016. PMID: 27239409 Free PMC article. Review.
-
Insulin fails to enhance mTOR phosphorylation, mitochondrial protein synthesis, and ATP production in human skeletal muscle without amino acid replacement.Am J Physiol Endocrinol Metab. 2012 Nov 1;303(9):E1117-25. doi: 10.1152/ajpendo.00067.2012. Epub 2012 Sep 11. Am J Physiol Endocrinol Metab. 2012. PMID: 22967500 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous